Chemotherapy vs targeted therapy

Chemotherapy is designed to damage or stop rapidly dividing cells, so it can affect some healthy tissues that renew quickly. Targeted therapy is developed for a defined protein, gene change, or cell pathway involved in a cancer’s growth or survival. A target must be present and clinically relevant; a test result alone does not guarantee that a targeted medicine will work.

Chemotherapy may be considered when the cancer is known to respond to a chemotherapy medicine, when no actionable target has been found, or when treatment needs to address cancer cells across multiple sites. It can be used before surgery, after surgery, for advanced disease, or with another therapy. Previous treatment and blood, kidney, and liver results influence the specific regimen.

Targeted therapy may be considered when testing identifies a target for which a suitable medicine exists and the cancer setting supports its use. The test may examine tumour tissue, circulating tumour material, or an inherited alteration, depending on the question. The team checks whether the target is still present, whether resistance has emerged, and whether other medicines could interact with treatment.

Chemotherapy side effects can include nausea, tiredness, mouth soreness, hair loss, reduced blood counts, and infection risk. Targeted medicines have different effects according to the pathway they block; possible concerns include diarrhoea, skin or nail changes, high blood pressure, liver-test changes, heart effects, or infusion reactions. Report new or worsening symptoms promptly, especially severe diarrhoea, chest symptoms, breathing difficulty, fever, or a widespread rash.

If neither option fits, the alternatives may include surgery, radiotherapy, hormone treatment, immunotherapy, another systemic medicine, a clinical trial discussion with the oncology team, or symptom-focused care. A targeted treatment can stop working when cancer cells change, so a new biopsy or molecular review may be useful before choosing the next line.

Clinicians weigh the cancer’s site and stage, pathology, molecular test results, prior treatments, symptoms, organ function, and the aim of care. They also consider the route of administration, monitoring burden, interactions, and your preferences. Ask which target was found, what the test can and cannot show, how response will be measured, and which symptoms require same-day advice.